Literature DB >> 6208152

Monoclonal antibodies: technology and application to gram-negative infections.

L S Young.   

Abstract

Monoclonal antibodies have obvious diagnostic and therapeutic applications in infectious diseases. The technology for producing these highly specific reagents is readily available and we have produced monoclonal antibodies against the core glycolipid (endotoxin) region of gram-negative bacilli and the O-antigens of Pseudomonas aeruginosa. These antibodies are protective by different mechanisms and more than one antibody against a bacterium may give enhanced protection. Use of antibodies plus antimicrobial therapy may yield optimal results.

Entities:  

Mesh：

Substances：

Year:  1984        PMID： 6208152     DOI： 10.1007/bf01645970

Source DB:  PubMed          Journal:  Infection        ISSN： 0300-8126            Impact factor:   3.553


  23 in total

1.  Functional role of antibody against "core" glycolipid of Enterobacteriaceae.

Authors:  L S Young; P Stevens; J Ingram
Journal:  J Clin Invest       Date:  1975-10       Impact factor: 14.808

2.  Structure of the Core oligosaccharide from the lipopolysaccharide of Pseudomonas aeruginosa PAC1R and its defective mutants.

Authors:  P S Rowe; P M Meadow
Journal:  Eur J Biochem       Date:  1983-05-02

3.  Antibody producing human-human hybridomas. I. Technical aspects.

Authors:  L Olsson; H Kronstrøm; A Cambon-De Mouzon; C Honsik; T Brodin; B Jakobsen
Journal:  J Immunol Methods       Date:  1983-06-24       Impact factor: 2.303

4.  Functional properties of anti-group B streptococcal monoclonal antibodies.

Authors:  M C Harris; S D Douglas; G B Kolski; R A Polin
Journal:  Clin Immunol Immunopathol       Date:  1982-09

5.  Cooperative immunoassays: ultrasensitive assays with mixed monoclonal antibodies.

Authors:  P H Ehrlich; W R Moyle
Journal:  Science       Date:  1983-07-15       Impact factor: 47.728

6.  Antibacterial activity of a human monoclonal antibody to haemophilus influenzae type B capsular polysaccharide.

Authors:  K W Hunter; G W Fischer; V G Hemming; S R Wilson; R J Hartzman; J N Woody
Journal:  Lancet       Date:  1982-10-09       Impact factor: 79.321

7.  Protective human hybridoma antibody to tetanus toxin.

Authors:  F Gigliotti; R A Insel
Journal:  J Clin Invest       Date:  1982-12       Impact factor: 14.808

8.  Monoclonal antibodies directed against a cell surface-exposed outer membrane protein of Haemophilus influenzae type b.

Authors:  S M Robertson; C F Frisch; P A Gulig; J R Kettman; K H Johnston; E J Hansen
Journal:  Infect Immun       Date:  1982-04       Impact factor: 3.441

9.  Isolation of hybridoma cell lines and characterization of monoclonal antibodies against cholera enterotoxin and its subunits.

Authors:  M Robb; J C Nichols; S K Whoriskey; J R Murphy
Journal:  Infect Immun       Date:  1982-10       Impact factor: 3.441

10.  Protection of mice from experimental infection with type III group B Streptococcus using monoclonal antibodies.

Authors:  M L Egan; D G Pritchard; H C Dillon; B M Gray
Journal:  J Exp Med       Date:  1983-09-01       Impact factor: 14.307
View more
  3 in total

Review 1.  Immunoprophylaxis and immunotherapy of gram-negative sepsis and shock with antibodies to core glycolipids and lipid A of bacterial lipopolysaccharides.

Authors:  I G Mitov; D G Terziiski
Journal:  Infection       Date:  1991 Nov-Dec       Impact factor: 3.553

2.  Endotoxin inactivation in plasma from septic patients: an in vitro study.

Authors:  P Olofsson; C Olofsson; G Nylander; P Olsson
Journal:  World J Surg       Date:  1986-04       Impact factor: 3.352

3.  Monoclonal antibodies and immobilized antibodies. Patents and literature.

Authors:  R J Linhardt
Journal:  Appl Biochem Biotechnol       Date:  1985-06       Impact factor: 2.926
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.